Maxim upgrades Daré Bioscience on extended cash runway, commercial launch

Dare Bioscience

04/09/2025 17:32

** Brokerage Maxim upgrades women's health firm Daré Bioscience DARE.O to "buy" from "hold" with a price target of $8

** Brokerage expects upside from Daré's $17.6 million fundraise in July 2025 via the at-the-market program and a $6 million grant, saying the funds extend the runway into 2H26

** Brokerage sees the initial launch of topical sildenafil as a near-term catalyst and the launch is targeted for the fourth quarter of 2025

** Topical sildenafil is an experimental cream used to treat female sexual arousal disorder

** "While additional funding will likely be required, we view the upcoming launch as an important milestone that enhances visibility and validates the commercial opportunity" - brokerage

** Including session's move, DARE stock down 33.3% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))